21
Views
5
CrossRef citations to date
0
Altmetric
Research Article

Antisense Oligonucleotides Complementary to Bax Transcripts Reduce the Susceptibility of B-cell Chronic Lymphocytic Leukaemia Cells to Apoptosis in a Bcl-2 Independent Manner

, , &
Pages 2003-2009 | Published online: 03 Aug 2009

  • [Line 14759]Reed, J.C. (1998) "Molecular biology of chronic lymphocytic leukemia: implications for therapy", Semin, Hematol. 35, 3-13.
  • [Line 14787]Foon, K.A., Rai, K.R. and Gale, R.P. (1990) "Chronic lymphocytic leukemia: new insights into biology and therapy". Ann. Intern. Med. 113, 525-539.
  • [Line 14817]Rozman, C. and Montserrat, E. (1995) "Chronic lymphocytic leukemia", N. Engl. J. Med. 333, 1052-1057.
  • [Line 14846]Korsmeyer, S.J. (1992) "Bel-2 initiates a new catogory of oncogenes: regulators of cell death", Blood 80, 879-886.
  • [Line 14874]Oltvai, Z.N., Milliman, C.L. and Korsmeyer, S.J. (1993) "Bel-2 heterodimerizes in vitro with a conserved homolog, bax, that accelerates programmed cell death", Cell 74, 609-619.
  • [Line 14904]Hanada, M., Delia, D., Aiello, A., Stadtmauer, E. and Reed, J.C. (1993) "bel-2 gene hypomethylation and high level expression in B-cell chronic lymphocytic leukemia", Blood 82, 1820-1828.
  • [Line 14936]Pepper, C., Bentley, P. and Hoy, T. (1996) "Regulation of clinical chemoresistance by bel-2 and bax oncoproteins in B-cell chronic lymphocytic leukaemia", Br. J. Haematol. 95, 513-517.
  • [Line 14966]Aguilar-Santelises, M., Rottenberg, M.E., Lewin, N., Mellstedl, H. and Jondal, M. (1996) "Bel-2, bax and p53 expression in B CLL in relation to in vitro survival and clinical progression", Int. J. Cancer 69, 114-119.
  • [Line 14998]Pepper, C., Thomas, A., Hoy, T., Cotter, F. and Bentley, P. (1999) "Antisense-mediated suppression of BeI-2 highlights its pivotal role in failed apoptosis in B-cell chronic lymphocytic leukaemia", Br. J. Haematol. 107, 611-615.
  • [Line 15030]Reed, J.C., Tsujimoto, Y., Alpers, J.D., Croce, C.M. and Nowell, P.C. (1987) "Regulation of bel-2 proto-oncogene expression during normal human lymphocyte proliferation", Science 236, 1295-1299.
  • [Line 15062]Miyashita, T. and Reed, J.C. (1995) "Tumor suppressor p53 is a direct transcriptional activator of human Bax gene", Cell 80, 293-299.
  • [Line 15091]Binct, J.L., Auquier, A., Dighiero, G., Chastang, C., Piguet, H., Goasguen, J., Vaugier, G., Potron, G., Colona, P., Oberling, F., Thomas, M., Tchemia, G., Jacquillat, C. and Boivin, P. (1981) "A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis". Cancer 48, 198-206.
  • [Line 15132]Moulding, D.A., Giles, R.V., Spiller, D.G., White, M.R.H., Tidd, D.M. and Edwards, S.W. (2000) "Apoptosis is rapidly triggered by antisense depletion of MCL-1 in differentiating U937 cells", Blood 96, 1756-1763.
  • [Line 15165]Ferlini, C., Di Cesare, S., Rainaldi, G., Malorni, W., Samoggia, P., Biselli, R. and Fattorossi, A. (1996) "Flow cytometrie analysis of the early phases of apoptosis by cellular and nuclear techniques", Cytometry 24, 106-115.
  • [Line 15199]Knudson, C.M. and Korsmeyer, S.J. (1997) "BeI-2 and Bax function independently to regulate cell death", Nat. Genet. 16, 358-363.
  • [Line 15228]Pepper, C., Hoy, T. and Beutley, D.P. (1997) "Bel-2/Bax ratios in chronic lymphocytic leukaemia and their correlation with in vitro apoptosis and clinical resistance". Br. J. Cancer 76, 935-938.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.